RxSight Q1 2026 revenue falls, guidance affirmed
RxSight, Inc. reported first quarter 2026 sales of $30.9 million, down 18.5% from a year earlier, mainly due to lower Light Delivery Device volumes, while Light Adjustable Lens procedures decreased 0.4% year over year.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
RxSight, Inc. reported first quarter 2026 sales of $30.9 million, down 18.5% from a year earlier, mainly due to lower Light Delivery Device volumes, while Light Adjustable Lens procedures decreased 0.4% year over year. Gross profit margin improved to 76.1% from 74.8% on a richer lens mix.
Total operating expenses rose to $41.3 million from $39.0 million as the company expanded its global commercial and support teams. Net loss widened to $15.9 million, or $0.38 per share, versus $8.2 million, or $0.20 per share, with adjusted net loss at $7.9 million, or $0.19 per share. Cash, cash equivalents and short-term investments totaled $217.9 million as of March 31, 2026. RxSight reiterated 2026 revenue guidance of $120 to $135 million and gross margin guidance of 70% to 72%, and now expects operating expenses at the high end of its prior $150 to $160 million range.
Positive
- None.
Negative
- Q1 2026 revenue declined 18.5% year over year to $30.9 million, with Light Adjustable Lens procedures down 0.4%, signaling weaker near-term growth momentum despite product adoption efforts.
- Profitability deteriorated meaningfully, as net loss widened to $15.9 million ($0.38 per share) from $8.2 million ($0.20 per share), and adjusted net loss increased to $7.9 million, indicating rising costs and negative operating leverage.
Insights
Revenue declined and losses widened, but full-year sales and margin guidance were reaffirmed.
RxSight delivered Q1 2026 sales of $30.9 million, an 18.5% year-over-year decline, mainly from lower Light Delivery Device units, while Light Adjustable Lens procedures were essentially flat. Despite lower volume, gross profit margin expanded to 76.1%, helped by a higher mix of lens sales.
Operating expenses rose to $41.3 million, up from $39.0 million, reflecting continued commercial and support hiring. Net loss nearly doubled to $15.9 million, or $0.38 per share, and adjusted net loss reached $7.9 million, or $0.19 per share. These figures indicate heavier spending and negative operating leverage on a smaller revenue base.
Management reaffirmed 2026 revenue guidance of $120–$135 million and gross margin of 70–72%, while indicating operating expenses should land at the high end of the prior $150–$160 million range and stock-based compensation of $30–$32 million. With $217.9 million in cash, cash equivalents and short-term investments as of March 31, 2026, the company maintains a sizable liquidity cushion to support growth initiatives.
8-K Event Classification
Key Figures
Key Terms
Light Adjustable Lens medical
Light Delivery Devices medical
gross profit margin financial
non-GAAP financial measures financial
stock-based compensation financial
adjusted net loss financial
Offering Details
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did RxSight (RXST) perform financially in Q1 2026?
What were RxSight (RXST) gross margin and operating expenses in Q1 2026?
What 2026 financial guidance did RxSight (RXST) provide?
What is RxSight (RXST)’s cash position as of March 31, 2026?
How did RxSight (RXST) Light Adjustable Lens and device volumes trend in Q1 2026?
What non-GAAP results did RxSight (RXST) report for Q1 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 6, 2026, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
The following exhibit is furnished as part of this report:
Exhibit number |
|
Description |
99.1 |
|
Press Release dated May 6, 2026. |
104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
RxSight, Inc. |
|
|
|
|
Date: |
May 6, 2026 |
By: |
/s/ Mark Wilterding |
|
|
|
Name: Mark Wilterding |
Exhibit 99.1
RXSIGHT, INC. REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES FULL-YEAR SALES OUTLOOK
Aliso Viejo, Calif. – May 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026.
Strategic Highlights and Recent Developments
“We are encouraged by the stabilizing business trends and the initial progress from our ongoing commercial initiatives,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “As we continue to refine these efforts, investing in both our team and our pipeline, we are confident that we can continue to build momentum across the company and reach the full potential of our technology for patients and practices.”
First Quarter Financial Results
In the first quarter of 2026, the company reported sales of $30.9 million, down 18.5% compared to the prior year, largely reflecting lower LDD unit volumes, consistent with expectations. LAL procedures decreased 0.4% year over year.
First quarter gross profit margin of 76.1% increased from 74.8% in the prior‑year period, primarily driven by a favorable shift in product mix toward LAL sales.
Total operating expenses were $41.3 million versus $39.0 million in the year-ago period. The increase was primarily driven by the continued expansion of our global commercial and support teams.
In the first quarter of 2026, the company reported a net loss of $(15.9) million, or $(0.38) per basic and diluted share, compared to a net loss of $(8.2) million, or $(0.20) per basic and diluted share in the first quarter of 2025. Adjusted net loss in the first quarter of 2026 was $(7.9) million, or $(0.19) per basic and diluted share, compared to an adjusted net loss of $(1.1) million, or $(0.03) per basic and diluted share in the first quarter of 2025.
As of March 31, 2026, cash, cash equivalents and short-term investments totaled $217.9 million.
2026 ASCRS Highlights
At the recent ASCRS annual meeting, RxSight technology was featured across multiple scientific presentations addressing refractive accuracy, complex cases and evolving treatment strategies. This rapidly expanding body of clinical evidence highlighted both the versatility and impact of adjustability. In addition, the conference included presentations by Dr. Szabo, who reported binocular LAL outcomes in which 93.1% of patients achieved simultaneous 20/20 or better distance and J1 or better near, as well as a meta-analysis by Dr. Rabinovitch, demonstrating pooled accuracy with the LAL was 91.2% within 0.50 diopters of target refraction.
2026 Guidance
The company’s 2026 financial guidance is as follows:
Conference Call
On Wednesday, May 6, 2026, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its first quarter 2026 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 2630350. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL/LAL+, collectively the “LAL”), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Forward-Looking Statements
This press release contains forward-looking statements, including: including statements regarding the company’s expectations related to stabilizing business trends; the initial progress from its ongoing
commercial initiatives; ongoing refinement of its commercial efforts; continued investments in its team and pipeline; its ability to build momentum across the company; and its ability to reach the full potential of its technology for patients and practices. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the three months ended March 31, 2026, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
RxSight, Inc., the RxSight Light Adjustable Lens LAL, LAL+, and LDD are trademarks of RxSight, Inc.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
RxSight, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS (UNAUDITED)
(In thousands, except share and per share amounts)
|
|
|
|
|
|
|
|
||
|
|
Three Months Ended March 31, |
|
|
|||||
|
|
2026 |
|
|
2025 |
|
|
||
|
|
|
|
|
|
|
|
||
Sales |
|
$ |
30,893 |
|
|
$ |
37,895 |
|
|
Cost of sales |
|
|
7,395 |
|
|
|
9,566 |
|
|
Gross profit |
|
|
23,498 |
|
|
|
28,329 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
||
Selling, general and administrative |
|
|
31,855 |
|
|
|
28,636 |
|
|
Research and development |
|
|
9,472 |
|
|
|
10,367 |
|
|
Total operating expenses |
|
|
41,327 |
|
|
|
39,003 |
|
|
Loss from operations |
|
|
(17,829 |
) |
|
|
(10,674 |
) |
|
Other income (expense), net: |
|
|
|
|
|
|
|
||
Interest expense |
|
|
(3 |
) |
|
|
(6 |
) |
|
Interest and other income |
|
|
1,954 |
|
|
|
2,508 |
|
|
Loss before income taxes |
|
|
(15,878 |
) |
|
|
(8,172 |
) |
|
Income tax expense |
|
|
6 |
|
|
|
18 |
|
|
|
|
|
|
|
|
|
|
||
Net loss |
|
$ |
(15,884 |
) |
|
$ |
(8,190 |
) |
|
Other comprehensive loss |
|
|
|
|
|
|
|
||
Unrealized loss on short-term investments |
|
|
(120 |
) |
|
|
(157 |
) |
|
Foreign currency translation gain |
|
|
— |
|
|
|
6 |
|
|
Total other comprehensive loss |
|
|
(120 |
) |
|
|
(151 |
) |
|
|
|
|
|
|
|
|
|
||
Comprehensive loss |
|
$ |
(16,004 |
) |
|
$ |
(8,341 |
) |
|
|
|
|
|
|
|
|
|
||
Net loss per share: |
|
|
|
|
|
|
|
||
Basic & diluted |
|
$ |
(0.38 |
) |
|
$ |
(0.20 |
) |
|
Weighted-average shares used in computing net loss per share: |
|
|
|
|
|
|
|
||
Attributable to common stock, basic & diluted |
|
|
41,306,110 |
|
|
|
40,509,646 |
|
|
RxSight, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share and per share amounts)
|
|
March 31, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
|
|
(Unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
17,573 |
|
|
$ |
19,949 |
|
Short-term investments |
|
|
200,307 |
|
|
|
208,179 |
|
Accounts receivable, net |
|
|
22,443 |
|
|
|
23,383 |
|
Inventories, net |
|
|
34,869 |
|
|
|
31,559 |
|
Prepaid and other current assets |
|
|
4,032 |
|
|
|
4,389 |
|
Total current assets |
|
|
279,225 |
|
|
|
287,459 |
|
Property and equipment, net |
|
|
13,232 |
|
|
|
13,056 |
|
Operating leases right-of-use assets |
|
|
9,760 |
|
|
|
9,959 |
|
Restricted cash |
|
|
750 |
|
|
|
750 |
|
Other assets |
|
|
1,026 |
|
|
|
590 |
|
Total assets |
|
$ |
303,993 |
|
|
$ |
311,814 |
|
Liabilities and stockholders' equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
7,124 |
|
|
$ |
5,296 |
|
Accrued expenses and other current liabilities |
|
|
18,748 |
|
|
|
19,795 |
|
Lease liabilities |
|
|
1,504 |
|
|
|
1,162 |
|
Total current liabilities |
|
|
27,376 |
|
|
|
26,253 |
|
Long-term lease liabilities |
|
|
9,322 |
|
|
|
9,878 |
|
Other long-term liabilities |
|
|
— |
|
|
|
— |
|
Total liabilities |
|
|
36,698 |
|
|
|
36,131 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders' equity: |
|
|
|
|
|
|
||
Common stock, $0.001 par value, 900,000,000 shares authorized, |
|
|
41 |
|
|
|
41 |
|
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued |
|
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
|
944,244 |
|
|
|
936,628 |
|
Accumulated other comprehensive (loss) income |
|
|
(67 |
) |
|
|
53 |
|
Accumulated deficit |
|
|
(676,923 |
) |
|
|
(661,039 |
) |
Total stockholders' equity |
|
|
267,295 |
|
|
|
275,683 |
|
Total liabilities and stockholders' equity |
|
$ |
303,993 |
|
|
$ |
311,814 |
|
Non-GAAP Financial Measures
To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including adjusted net earnings (loss), and adjusted net earnings (loss) per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because this expense is non-cash in nature and we believe excluding this item provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.
We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
Adjusted Net Earnings (Loss) and Adjusted Net Earnings (Loss) Per Share
Adjusted net earnings (loss) is a non-GAAP financial measure that we define as net earnings (loss) adjusted for stock-based compensation. We believe adjusted net earnings (loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.
Reconciliations of net earnings (loss) to adjusted net earnings (loss) and the presentation of adjusted net earnings (loss) per share, basic and diluted, are as follows:
|
|
Three months ended March 31, |
|
|
|||||
|
|
2026 |
|
|
2025 |
|
|
||
Common Stock |
|
|
|
|
|
|
|
||
Numerator: |
|
|
|
|
|
|
|
||
Net loss available to stockholders, basic and diluted |
|
$ |
(15,884 |
) |
|
$ |
(8,190 |
) |
|
Add: |
|
|
|
|
|
|
|
||
Stock-based compensation |
|
|
7,945 |
|
|
|
7,140 |
|
|
Adjusted net loss available to common stockholders, basic and diluted: |
|
$ |
(7,939 |
) |
|
$ |
(1,050 |
) |
|
|
|
|
|
|
|
|
|
||
Denominator: |
|
|
|
|
|
|
|
||
Weighted-average shares outstanding, basic and diluted |
|
|
41,306,110 |
|
|
|
40,509,646 |
|
|
Adjusted net loss per share, basic and diluted |
|
$ |
(0.19 |
) |
|
$ |
(0.03 |
) |
|